ArticleAlimentary pharmacology & therapeutics2013
Genetic risk factors for Clostridium difficile infection in ulcerative colitis.
Article in Alimentary pharmacology & therapeutics, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 38 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
38 citing papers in PubMed, 2 syntheses or guidelines pooled it, 62 citations in OpenAlex.
- Systematic review: gastrointestinal infection and incident inflammatory bowel disease.Alimentary pharmacology & therapeutics · 2020Pooled it
- Risk factors forJournal of global health · 2017Pooled it
- Association betweenmedRxiv : the preprint server for health sciences · 2026Article
- Machine Learning Model Predicts Recurrent Clostridioides difficile Infection in Patients With Inflammatory Bowel Disease (Recur CDI-IBD).The American journal of gastroenterology · 2026Article
- Article
- Antibacterial Activity of the p53 Tumor Suppressor Protein-How Strong Is the Evidence?International journal of molecular sciences · 2025Review
- Global Patterns ofCrohn's & colitis 360 · 2025Article
- Current Approaches to Ulcerative Colitis Management: A Comprehensive Overview of Methodologies and Treatments.Infectious disorders drug targets · 2025Review
- Genetic variation in the human leukocyte antigen region confers susceptibility to Clostridioides difficile infection.Scientific reports · 2023Article
- Inflammatory bowel disease andTherapeutic advances in gastroenterology · 2023Review
- Analysis of Intestinal Mycobiota of Patients with Clostridioides difficile Infection among a Prospective Inpatient Cohort.Microbiology spectrum · 2022Article
- Global trends in intestinal flora and ulcerative colitis research during the past 10 years: A bibliometric analysis.Frontiers in microbiology · 2022Article
- Management and characteristics of patients suffering fromThe European journal of general practice · 2021Observational
- Associations between CD160 polymorphisms and autoimmune thyroid disease: a case-control study.BMC endocrine disorders · 2021Article
- Article
- The role of gastrointestinal pathogens in inflammatory bowel disease: a systematic review.Therapeutic advances in gastroenterology · 2021Review
- Variants at the MHC Region Associate With Susceptibility toFrontiers in immunology · 2021Article
- Management of Recurrent Clostridioides Infection: A Difficile Problem in Inflammatory Bowel Disease Patients.Digestive diseases and sciences · 2020Article
- Microbiota inBiomedicines · 2020Article
- Mechanisms of Paeonia lactiflora in Treatment of Ulcerative Colitis: A Network Pharmacological Study.Medical science monitor : international medical journal of experimental and clinical research · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 3 institutions in 1 country.
Funding
Abstract
backgroundPatients with inflammatory bowel disease (IBD) are at higher risk for Clostridium difficile infection (CDI). Disruption of gut microbiome and interaction with the intestinal immune system are essential mechanisms for pathogenesis of both CDI and IBD. Whether genetic polymorphisms associated with susceptibility to IBD are also associated with risk of CDI is unknown.
aimsTo use a well-characterised and genotyped cohort of patients with UC to (i) identify clinical risk factors for CDI; (ii) examine if any of the IBD genetic risk loci were associated with CDI; and (iii) to compare the performance of predictive models using clinical and genetic risk factors in determining risk of CDI.
methodsWe used a prospective registry of patients from a tertiary referral hospital. Medical record review was performed to identify all ulcerative colitis (UC) patients within the registry with a history of CDI. All patients were genotyped on the Immunochip. We examined the association between the 163 risk loci for IBD and risk of CDI using a dominant genetic model. Model performance was examined using receiver operating characteristics curves.
resultsThe study included 319 patients of whom 29 developed CDI (9%). Female gender and pancolitis were associated with increased risk, while use of anti-TNF was protective against CDI. Six genetic polymorphisms including those at TNFRSF14 [Odds ratio (OR) 6.0, P-value 0.01] were associated with increased risk while 2 loci were inversely associated. On multivariate analysis, none of the clinical parameters retained significance after adjusting for genetics. Presence of at least one high-risk locus was associated with an increase in risk for CDI (20% vs. 1%) (P = 6 × 10⁻⁹). Compared to 11% for a clinical model, the genetic loci explained 28% of the variance in CDI risk and had a greater AUROC.
conclusionHost genetics may influence susceptibility to Clostridium difficile infection in patients with ulcerative colitis.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.